NeuroRx, Relief Therapeutics declare results of RLF-100 clinical trials

U.S.-based pharmaceutical company NeuroRx Inc., along with Relief Therapeutics Holding AG, a Swiss drug development company, have reportedly declared that aviptadil (RLF-100) clinical trials have showcased quick recuperation of respiratory failures among critical patients of COVID-19. According to independent researchers, RLF-100 apparently blocks the multiplication of the SARS coronavirus in human lung cells as well as monocytes.

The first rapid clinical recuperation report was posted by doctors from Houston Methodist Hospital. It described the recovery of a 54-year-old man who contracted COVID-19 while being treated for rejection of a multiple lung transplant and was taken off the ventilator within four days of treatment.

Similar outcomes were observed in more than 15 cases treated under emergency use IND (Investigational New Drug), sources claimed. The FDA extended its access protocols which are available to critically ill patients admitted to the current Phase 2/3 FDA trials

Sources with relevant information cited that critically ill COVID-19 patients witnessed a quick recovery from pneumonitis, as displayed by the findings on their x-ray reports. Moreover, an improvement in the patients’ blood oxygen levels were seen alongside a 50% decrease in test center markers related to COVID-19 inflammation.

Prof. Jonathan Javitt, CEO and Chairman of NeuroRx was reported stating that other antiviral agents have failed to show such fast recuperation from a viral disease and exhibited inhibitions towards the multiplication of the virus. He further said that placebo-controlled trials are being carried out by NeuroRx in order to analyze the observations made during open-label and case-control studies.

For those uninitiated, RF-100 is an antiviral agent that has been developed as a Material Threat Medical Countermeasure.

The FDA has reportedly granted Fast Track designation to this antiviral, which is developed through a joint venture agreement among National Institute of Health and numerous other federal agencies, the medicine is being developed as a Material Threat Medical Countermeasure.

 

Source Credits: https://www.prnewswire.com/news-releases/rlf-100-aviptadil-clinical-trial--showed-rapid-recovery-from-respiratory-failure-and-inhibition-of-coronavirus-replication-in-human-lung-cells-301104384.html